Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozanimod - Celgene Corporation

Next Previous
Drug Profile

Ozanimod - Celgene Corporation

Alternative Names: BMS-986374; Ozanimod-HCl; Ozanimod-hydrochloride; RPC-1063; RPC-1063-HCl; ZEPOSIA

Latest Information Update: 29 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer Bristol-Myers Squibb; Celgene Corporation; Receptos
  • Class Amines; Anti-inflammatories; Benzene derivatives; Indenes; Nitriles; Oxadiazoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis; Ulcerative colitis
  • Phase III Crohn's disease

Most Recent Events

  • 15 May 2025 Celgene terminates phase III trial in Multiple sclerosis (Treatment-experienced) in Canada, Puerto Rico, USA due to change business objective (PO) (NCT04140305)
  • 08 Apr 2025 Phase-III clinical trials in Multiple sclerosis (Treatment-experienced, In children, In adolescents) in Italy, Mexico, Poland, Portugal, USA, Romania, Spain, Turkey, Taiwan (PO) (NCT06408259)
  • 07 Mar 2025 Bristol-Myers Squibb terminates phase III trial in Ulcerative colitis in Taiwan and China (PO) (NCT05644665) due to change in business objectives (NCT05644665)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top